Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA

Executive Summary

An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings

You may also be interested in...



Mandatory FDA Review Of Pivotal Trial Protocols Urged In JAMA

Dartmouth researchers say that although FDA recommendations can strengthen study designs and improve outcome measures, sponsors often don’t follow agency’s advice or don’t even seek input in Phase III design.

Mandatory FDA Review Of Pivotal Trial Protocols Urged In JAMA

Dartmouth researchers say that although FDA recommendations can strengthen study designs and improve outcome measures, sponsors often don’t follow agency’s advice or don’t even seek input in Phase III design.

Learning From Its Successes? FDA Wants Feedback On All First-Cycle Actions For Assessment Program

Interviews with all sponsors that receive a first-cycle action, approvals as well as other outcomes, under PDUFA V’s new NME and original BLA review program will help FDA assess the program’s success.

Related Content

UsernamePublicRestriction

Register

PS046861

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel